NDAORALSYRUP
Approved
Mar 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HYCODAN (hydrocodone bitartrate and homatropine methylbromide) by Teva is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 1943.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCODAN is an oral syrup combination of hydrocodone bitartrate (mu-opioid receptor agonist) and homatropine methylbromide (anticholinergic agent) approved in 1943 for cough suppression. Hydrocodone acts centrally on the cough center while homatropine inhibits muscarinic acetylcholine receptors to reduce secretions. The product is indicated for symptomatic relief of cough in patients where an opioid-containing antitussive is appropriate.
$0.235MPart D
LOE ApproachingProduct is in late-stage lifecycle with minimal Part D utilization (13 claims in 2023), suggesting limited commercial investment and likely small team size with focus on transition planning.
Mechanism of Action
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYCODAN offers limited career growth given its LOE-approaching status and minimal job market presence (0 linked roles). This role is best suited for professionals seeking stability in legacy product management rather than innovation, growth, or high-visibility brand launches.
Brand Manager
Worked on HYCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.